Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery

Project Information

TrainCKDis

Grant agreement ID: 860977

DOI

10.3030/860977

Project closed

EC signature date 12 August 2019

Start date 1 January 2020

End date 30 June 2024

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 4 017 848,40

EU contribution

€ 4 017 848,40

Coordinated by

UNIVERSITE PARIS CITE
France

Periodic Reporting for period 2 - TrainCKDis (Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery)

Reporting period: 2022-01-01 to 2024-06-30

Summary of the context and overall objectives of the project

The goal of TrainCKDis is to provide high-level training in chronic kidney disease (CKD) - a global public health burden - to a new generation of highly achieving early stage researchers. TrainCKDis will develop scientific skills necessary for thriving careers in an expanding area that underpins innovative technological development across a range of diverse disciplines including nephrology, epidemiology, genetics, cell biology, and drug discovery at the interface of basic molecular, genetic and clinical research. We will achieve this by a unique combination of “hands-on” research training, non-academic placements, courses and workshops on scientific and transferable skills, facilitated by the consortium academic/non-academic composition.

Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, lasting longer than three months. CKD is an increasing global health problem; its prevalence and associated burden are rising worldwide1. CKD affects 10-15% of the population, with unexplained regional variation across Europe. About 70 million Europeans have suboptimal kidney function and are at increased risk of kidney failure, a fatal condition without renal replacement therapies (RRT) such as dialysis or transplantation.

The key research challenges are:
1) Identify genetic and epigenetic modifiers that predispose patients to CKD progression;
2) Uncover signalling pathways and innovative biomarkers essential for monitoring disease evolution and clinical trials outcomes;
3) Discover novel therapeutic targets to expand the limited CKD treatments.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Confidential. Not to be public yet.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

CKD progression rate varies considerably among individuals exposed to the same risk factor. We aim to understand the biological nature of CKD progression by capitalizing on data from unique human cohorts on deeply phenotyped individuals.

We cannot understand the molecular pathway leading to CKD progression yet and therefore it is more difficult to identify efficient biomarkers. The purpose of TrainCKDis is here to discover molecular signatures to predict CKD progression and possible treatment efficacy.

There is few treatment that are capable to slow down CKD progression. Through experimental in vivo and in vitro models for CKD, we aim to elucidate novel targetable molecular pathways.

As stated above CKD represents a global health problem affecting 10-15% of the population. CKD is associated with impaired quality of life, reduced life expectancy and risk of cardiovascular disease. The cost or treating CKD and its implication including kidney failure is high and a burden for healthcare system.

Logo